Purple Biotech Stock Analysis

Purple Stock Analysis Notes

The company has price-to-book ratio of 0.23. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Purple Biotech recorded earning per share (EPS) of 476.1. The entity last dividend was issued on the 21st of August 2020. The firm had 1:20 split on the 17th of September 2024. Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To find out more about Purple Biotech contact the company at 972 3 933 3121 or learn more at https://purple-biotech.com.

Purple Biotech Investment Alerts

Purple Biotech Upcoming and Recent Events

Purple Largest EPS Surprises

View All Earnings Estimates

Purple Biotech Environmental, Social, and Governance (ESG) Scores

Purple Stock Institutional Investors

Note, although Purple Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Purple Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.35 M.

Purple Profitablity

Management Efficiency

Purple Biotech has return on total asset (ROA) of (0.1283) % which means that it has lost $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.124) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to drop to -0.35 in 2025. Change To Liabilities is likely to gain to about 964.8 K in 2025, whereas Total Current Liabilities is likely to drop slightly above 3.8 M in 2025.

Technical Drivers

As of the 22nd of July, Purple Biotech holds the Semi Deviation of 3.05, coefficient of variation of 2940.83, and Risk Adjusted Performance of 0.039. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Purple Biotech, as well as the relationship between them.

Purple Biotech Price Movement Analysis

Purple Biotech Outstanding Bonds

Purple Biotech Predictive Daily Indicators

Purple Biotech Forecast Models

Purple Biotech's time-series forecasting models are one of many Purple Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Purple Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Purple Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Purple shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Purple Biotech. By using and applying Purple Stock analysis, traders can create a robust methodology for identifying Purple entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Purple analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Purple analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Purple Biotech stock analysis indicators help investors evaluate how Purple Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Purple Biotech shares will generate the highest return on investment. By understating and applying Purple Biotech stock analysis, traders can identify Purple Biotech position entry and exit signals to maximize returns.

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.